Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Context.—Controversies and uncertainty persist in prostate cancer grading. Objective.—To
update grading recommendations. Data Sources.—Critical review of the literature along with …

Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent
through several comprehensive profiling efforts, but little is known about the impact of this …

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an
initial diagnosis of prostate cancer and management options for localized, regional, and …

PURPOSE This guideline provides recommendations for available tissue-based prostate
cancer biomarkers geared toward patient selection for active surveillance, identification of …

Background Prostate tumor heterogeneity and biopsy undersampling pose challenges to
accurate, individualized risk assessment for men with localized disease. Objective To …

Purpose To endorse Cancer Care Ontario's guideline on Active Surveillance for the
Management of Localized Prostate Cancer. The American Society of Clinical Oncology …

Context Although the widespread use of prostate-specific antigen (PSA) has led to an early
detection of prostate cancer (PCa) and a reduction of metastatic disease at diagnosis, PSA …

Background The use of biomarkers for prostate cancer screening, diagnosis and prognosis
has the potential to improve the clinical management of the patients. Owing to inherent …